Christopher Ray Aker - 30 Jan 2025 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Reporting relationship: Sr. VP & General Counsel
Issuer ticker: RGLS
Reported as of: 30 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jan 2025, 17:00:05 UTC
Prior SEC filing: 15 Jan 2025
Next SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: Christopher Aker

Key filing fact

Christopher Ray Aker filed Form 4 for Regulus Therapeutics Inc. (RGLS) on 31 Jan 2025.

Key facts

This page summarizes Christopher Ray Aker's Form 4 filing for Regulus Therapeutics Inc. (RGLS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Jan 2025, 17:00.

Change

Previous filing in this sequence was filed on 15 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +487,500
Change %
Price: $0.000000
Shares after: 487,500
Date: 30 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 487,500
Exercise price: $1.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.